COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
暂无分享,去创建一个
[1] M. Ghosh,et al. Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients , 2022, Genes & diseases.
[2] M. Ghosh,et al. Chaperone-assisted E3 ligase CHIP: A double agent in cancer , 2021, Genes & diseases.
[3] Jianqing Xu,et al. Monitoring Coronavirus Disease 2019: A Review of Available Diagnostic Tools , 2021, Frontiers in Public Health.
[4] G. Esmat,et al. Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study , 2021, Journal of medical virology.
[5] M. S. Rezai,et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial , 2021, Clinical Therapeutics.
[6] Carolina Q. Sacramento,et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 , 2021, The Journal of antimicrobial chemotherapy.
[7] P. Taylor,et al. Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.
[8] K. Skorecki,et al. The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic , 2021, Frontiers in Endocrinology.
[9] Andy Charlwood,et al. HRM and the COVID‐19 pandemic: How can we stop making a bad situation worse? , 2021, Human Resource Management Journal.
[10] B. Medhi,et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.
[11] F. Vidal,et al. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH) , 2021, Expert opinion on pharmacotherapy.
[12] D. Barford,et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP , 2021, Proceedings of the National Academy of Sciences.
[13] D. Skovronsky,et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[14] D. Tegunov,et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir , 2021, Nature communications.
[15] A. Elfiky,et al. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico , 2021, Molecular Diversity.
[16] I. Al-Zakwani,et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia , 2020, International Journal of Infectious Diseases.
[17] S. Joshi,et al. Role of favipiravir in the treatment of COVID-19 , 2020, International Journal of Infectious Diseases.
[18] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[19] R. Porcher,et al. Remdesivir for COVID-19 in Europe: will it provide value for money? , 2020, The Lancet Respiratory Medicine.
[20] H. Keyvani,et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial , 2020, BMC Infectious Diseases.
[21] A. A. Onischuk,et al. Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections , 2020, Journal of Pharmaceutical Sciences.
[22] Jinzi J. Wu,et al. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients , 2020, Medicine.
[23] V. Belousov,et al. Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 , 2020 .
[24] Daniel P. Walsh,et al. Veno-venous extracorporeal membrane oxygenation allocation in the COVID-19 pandemic , 2020, Journal of Critical Care.
[25] H. Ogawa,et al. COVID-19-associated coagulopathy and disseminated intravascular coagulation , 2020, International Journal of Hematology.
[26] R. Bauer,et al. Antiviral activity of plant juices and green tea against SARS‐CoV‐2 and influenza virus , 2020, bioRxiv.
[27] H. Ogawa,et al. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation , 2020, International Journal of Infectious Diseases.
[28] D. Annane,et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study , 2020, EClinicalMedicine.
[29] D. Skovronsky,et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[30] Shahalam Khan,et al. Combating COVID-19: The role of drug repurposing and medicinal plants , 2020, Journal of Infection and Public Health.
[31] N. Al-Dhabi,et al. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach , 2020, Journal of Infection and Public Health.
[32] K. Sharun,et al. Ebselen, a new candidate therapeutic against SARS-CoV-2 , 2020, International Journal of Surgery.
[33] Samuel M. Galvagno,et al. Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019 , 2020, Anesthesia and analgesia.
[34] J. Qi,et al. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir , 2020, bioRxiv.
[35] C. del Rio,et al. Long-term Health Consequences of COVID-19. , 2020, JAMA.
[36] A. Ryo,et al. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico , 2020, Microorganisms.
[37] Jennifer L. Bell,et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.
[38] G. Landoni,et al. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence- , 2020, International Journal of Cardiology.
[39] C. Le Page,et al. Repurposing anticancer drugs for the management of COVID-19 , 2020, European Journal of Cancer.
[40] Liping Jiang,et al. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis , 2020, BMJ Supportive & Palliative Care.
[41] C. Shanmugam,et al. COVID-2019 – A comprehensive pathology insight , 2020, Pathology - Research and Practice.
[42] B. Coutard,et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis , 2020, Nature Communications.
[43] F. Frigieri,et al. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action , 2020, Thrombosis Research.
[44] M. Zhang,et al. Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial , 2020, Engineering.
[45] R. Singh,et al. Drug repurposing approach to fight COVID-19 , 2020, Pharmacological Reports.
[46] Á. Avezum,et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.
[47] Arthur S Slutsky,et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.
[48] Z. Natto,et al. A contemporary look at COVID-19 medications: available and potentially effective drugs. , 2020, European review for medical and pharmacological sciences.
[49] L. Tang,et al. Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 , 2020, European journal of clinical pharmacology.
[50] Yvette N. Lamb. Remdesivir: First Approval , 2020, Drugs.
[51] J. Shapiro,et al. Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[52] Q. de Mast,et al. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients , 2020, EBioMedicine.
[53] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[54] F. Drago,et al. The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review , 2020, Frontiers in Pharmacology.
[55] F. Saghafi,et al. Pharmacological treatments of COVID-19 , 2020, Pharmacological Reports.
[56] J. Eswari,et al. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities , 2020, European Journal of Pharmaceutical Sciences.
[57] Z. Lotfi,et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 , 2020, The Journal of antimicrobial chemotherapy.
[58] A. Davarpanah,et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.
[59] S. Merat,et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.
[60] Vivek Gupta,et al. Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges , 2020, Life Sciences.
[61] S. Jockusch,et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir , 2020, Scientific Reports.
[62] N. Savchuk,et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[63] E. Schenck,et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 , 2020, Clinical Immunology.
[64] T. Akahoshi,et al. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate , 2020, Journal of Infection and Chemotherapy.
[65] S. M. Asdaq,et al. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review , 2020, Journal of Infection and Public Health.
[66] M. Vargas,et al. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. , 2020, European review for medical and pharmacological sciences.
[67] J. Hewitt,et al. Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19 , 2020, Journal of clinical medicine.
[68] D. Mallardo,et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy , 2020, Journal for ImmunoTherapy of Cancer.
[69] A. Hussain,et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies , 2020, Biomedicine & Pharmacotherapy.
[70] M. Veettil,et al. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection , 2020, European Journal of Pharmacology.
[71] M. Bassetti,et al. Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19” , 2020, Open forum infectious diseases.
[72] F. Violi,et al. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? , 2020, Drugs.
[73] Zhihai Chen,et al. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients , 2020, Journal of acquired immune deficiency syndromes.
[74] Oliver Schnell,et al. Issues for the management of people with diabetes and COVID-19 in ICU , 2020, Cardiovascular Diabetology.
[75] G. Paolisso,et al. Covid-19 Kills More Men Than Women: An Overview of Possible Reasons , 2020, Frontiers in Cardiovascular Medicine.
[76] F. Cadegiani,et al. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) , 2020, Medical Hypotheses.
[77] A. von Brunn,et al. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19 , 2020, Medicine in Drug Discovery.
[78] Y. Muhammed. Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment , 2020, Biosafety and Health.
[79] K. Miyazono,et al. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series , 2020, Critical Care.
[80] J. Vinetz,et al. Dexamethasone in the management of covid -19 , 2020, BMJ.
[81] Christoph Nitsche,et al. The SARS-CoV-2 main protease as drug target , 2020, Bioorganic & Medicinal Chemistry Letters.
[82] A. Prakash,et al. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis , 2020, Indian journal of pharmacology.
[83] Xiuhong Zhang,et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19 , 2020, International Immunopharmacology.
[84] J. Wise. Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency , 2020, BMJ.
[85] M. Parnham,et al. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections , 2020, Free Radical Biology and Medicine.
[86] Mohammad Tariqur Rahman. Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19 , 2020, Journal of Herbal Medicine.
[87] P. Lotti,et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study , 2020, The Journal of Infection.
[88] A. A. Mutair,et al. Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis , 2020, medRxiv.
[89] H. Rahman,et al. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts , 2020, Le Pharmacien Hospitalier et Clinicien.
[90] I. Youngster,et al. Ibuprofen use and clinical outcomes in COVID-19 patients , 2020, Clinical Microbiology and Infection.
[91] W. Ye,et al. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors , 2020, International Journal of Antimicrobial Agents.
[92] J. Fraser,et al. ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review , 2020, Critical Care.
[93] N. Mondaini. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management? , 2020, The world journal of men's health.
[94] A. Fanin,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19 , 2020, Internal and Emergency Medicine.
[95] A. Rodríguez-Morales,et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 , 2020, Annals of Clinical Microbiology and Antimicrobials.
[96] P. Cecchini,et al. COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients , 2020, Journal of medical virology.
[97] Yanxia Huang,et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID‐19 , 2020, Journal of medical virology.
[98] Zhiquan Hu,et al. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals , 2020, Frontiers in Public Health.
[99] S. Ayis,et al. The association between treatment with heparin and survival in patients with Covid-19 , 2020, Journal of Thrombosis and Thrombolysis.
[100] W. Xu,et al. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases , 2020, International journal of molecular sciences.
[101] Sumra Wajid Abbasi,et al. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment , 2020, Journal of biomolecular structure & dynamics.
[102] G. Lemperle,et al. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? , 2020, Internal and Emergency Medicine.
[103] Francia Carolina Acosta Saltos,et al. Entry of SARS-CoV2 through the Basal Surface of Alveolar Endothelial Cells – A Proposed Mechanism Mediated by CD147 in COVID-19 , 2020 .
[104] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[105] K. Naber,et al. Thymoquinone: shield and sword against SARS-CoV-2 , 2020, Precision Nanomedicine.
[106] Xilong Deng,et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial , 2020, Med.
[107] K. Burgess,et al. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps , 2020, ACS medicinal chemistry letters.
[108] A. Gasbarrini,et al. Sarilumab use in severe SARS-CoV-2 pneumonia , 2020, EClinicalMedicine.
[109] Ana Allende,et al. SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area , 2020, Water Research.
[110] B. Coutard,et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase , 2020, bioRxiv.
[111] P. Marik,et al. Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19 , 2020, Frontiers in Medicine.
[112] Hongyu Zhao,et al. Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men , 2020, bioRxiv.
[113] Renyi Wu,et al. An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.
[114] L. Amorosa,et al. An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.
[115] H. Yanai. Favipiravir: A Possible Pharmaceutical Treatment for COVID-19 , 2020 .
[116] V. Fuster,et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[117] I. Berindan‐Neagoe,et al. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 , 2020, Pharmacological Research.
[118] G. Racagni,et al. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? , 2020, Pharmacological Research.
[119] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[120] A. Elfiky,et al. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective , 2020, Journal of biomolecular structure & dynamics.
[121] D. Havlir,et al. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19 , 2020, The New England journal of medicine.
[122] Jerrine Joseph,et al. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach , 2020, Journal of biomolecular structure & dynamics.
[123] Arun K. Ghosh,et al. Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics , 2020, ChemMedChem.
[124] Nils Kucher,et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.
[125] E. Nicastri,et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.
[126] H. Ulrich,et al. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement , 2020, Stem Cell Reviews and Reports.
[127] Nan Tang,et al. SARS-CoV-2 and viral sepsis: observations and hypotheses , 2020, The Lancet.
[128] Madeeha Kamal,et al. Therapeutic management of patients with COVID-19: a systematic review , 2020, Infection Prevention in Practice.
[129] Jie Li,et al. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine , 2020, Journal of Integrative Medicine.
[130] S. Ünal,et al. Antiviral treatment of COVID-19 , 2020, Turkish journal of medical sciences.
[131] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[132] E. Decroly,et al. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites , 2020, Antiviral Research.
[133] Yan Zhang,et al. Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir , 2020, bioRxiv.
[134] Bhumi M. Shah,et al. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.
[135] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[136] W. Ageno,et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). , 2020, Blood transfusion = Trasfusione del sangue.
[137] M. Corbellino,et al. Baricitinib for COVID-19: a suitable treatment? – Authors' reply , 2020, The Lancet Infectious Diseases.
[138] Xuhui Huang,et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.
[139] C. Montecucco,et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.
[140] I. Vlodavsky,et al. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study , 2020, Clinical and translational science.
[141] Jiansheng Huang,et al. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 , 2020, Journal of clinical medicine.
[142] Duanqing Pei,et al. Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.
[143] Agency European Medicines. EMA advice on the use of NSAIDs for Covid-19 , 2020, Drug and Therapeutics Bulletin.
[144] C. Delaugerre,et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.
[145] Sven Van Poucke,et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies , 2020, Journal of clinical and translational hepatology.
[146] Y. Ho,et al. SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.
[147] A. Elfiky,et al. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study , 2020, Life Sciences.
[148] Ping Zhu,et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial , 2020, medRxiv.
[149] Xilong Deng,et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) , 2020, medRxiv.
[150] Bo Chen,et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.
[151] France Mentré,et al. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19 , 2020, medRxiv.
[152] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[153] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[154] Wu Zhong,et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.
[155] Z. Hong,et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.
[156] Jianjun Gao,et al. Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.
[157] Hongzhou Lu,et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.
[158] K. Nicolaides,et al. Maternal cardiac function in women at high risk for pre‐eclampsia treated with 150 mg aspirin or placebo: an observational study , 2020, BJOG : an international journal of obstetrics and gynaecology.
[159] D. Gurwitz. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics , 2020, Drug development research.
[160] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[161] Suranga L Senanayake. Drug repurposing strategies for COVID-19 , 2020, Future Drug Discovery.
[162] Erin E. Mulvihill,et al. Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism , 2020, Clinical medicine insights. Endocrinology and diabetes.
[163] Mubarak A. Alamri,et al. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.
[164] T. Pan,et al. Teicoplanin potently blocks the cell entry of 2019-nCoV , 2020, medRxiv.
[165] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[166] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[167] Kai Zhao,et al. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[168] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[169] Winnie Martinez,et al. National Institute of Diabetes and Digestive and Kidney Diseases , 2020, Definitions.
[170] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[171] M. Toumi,et al. Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al , 2020, Journal of market access & health policy.
[172] Shan Chang,et al. The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75 , 2020, Journal of enzyme inhibition and medicinal chemistry.
[173] Naveen Vankadari,et al. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 , 2020, Emerging microbes & infections.
[174] H. Naim,et al. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus , 2020, Emerging microbes & infections.
[175] D. Webb,et al. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease , 2019, British journal of pharmacology.
[176] M. Oyewumi,et al. Delivery Systems as Vital Tools in Drug Repurposing , 2019, AAPS PharmSciTech.
[177] Nermin S. Ahmed. Tadalafil: 15 years' journey in male erectile dysfunction and beyond , 2018, Drug development research.
[178] M. Lacouture,et al. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies , 2018, Breast Cancer Research and Treatment.
[179] S. Dudek,et al. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. , 2018, American journal of physiology. Lung cellular and molecular physiology.
[180] A. Tosti,et al. Safety concerns when using novel medications to treat alopecia , 2018, Expert opinion on drug safety.
[181] L. Ge,et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials , 2018, Acta Diabetologica.
[182] S. Lyapustina. Regulatory pitfalls and opportunities when repurposing for inhalation therapy. , 2018, Advanced drug delivery reviews.
[183] S. Newman. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. , 2018, Advanced drug delivery reviews.
[184] Deric M. Park,et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.
[185] L. Berrino,et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article , 2018, Inflammopharmacology.
[186] W. Xie,et al. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension , 2018, Laboratory Investigation.
[187] Peisheng Xu,et al. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. , 2017, Acta biomaterialia.
[188] E. Deeks. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection , 2016, Drugs.
[189] G. Raghu. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential , 2017, European Respiratory Review.
[190] Y. Furuta,et al. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[191] S. Perlman,et al. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.
[192] S. Perlman,et al. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.
[193] G. Sourvinos,et al. Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ , 2017, Oncotarget.
[194] N. Mikhailova,et al. Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice , 2017 .
[195] L. Ganju,et al. Broad-spectrum antiviral properties of andrographolide , 2017, Archives of Virology.
[196] A. Sarma,et al. Aspirin Use in Women: Current Perspectives and Future Directions , 2016, Current Atherosclerosis Reports.
[197] R. Saito,et al. Japanese Surveillance Systems and Treatment for Influenza , 2016, Current Treatment Options in Infectious Diseases.
[198] D. Raoult,et al. Fighting viruses with antibiotics: an overlooked path , 2016, International Journal of Antimicrobial Agents.
[199] C. Klemann,et al. Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system , 2016, Clinical and experimental immunology.
[200] D. Talmor,et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. , 2016, JAMA.
[201] H. Jun,et al. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control , 2016, Mediators of inflammation.
[202] T. Pan,et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.
[203] A. Bello,et al. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection , 2016, Antiviral Research.
[204] W. Oh,et al. Discovery of inhibitory materials against PEDV corona virus from medicinal plants , 2016 .
[205] A. Lambeir,et al. The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis , 2015, Front. Immunol..
[206] Nina Wronkowitz,et al. DPP4 in Diabetes , 2015, Front. Immunol..
[207] G. Bernard,et al. Prehospital Aspirin Use Is Associated With Reduced Risk of Acute Respiratory Distress Syndrome in Critically Ill Patients: A Propensity-Adjusted Analysis* , 2015, Critical care medicine.
[208] Zhi Cai,et al. Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study , 2015, Cell Biochemistry and Biophysics.
[209] O. Chupakhin,et al. [Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]. , 2015, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].
[210] A. Lefor,et al. Favipiravir: A New Medication for the Ebola Virus Disease Pandemic , 2014, Disaster Medicine and Public Health Preparedness.
[211] C. K. Edwards,et al. The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific Literature , 2014, International journal of molecular sciences.
[212] Chad E. Schroeder,et al. Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication , 2014, ACS chemical biology.
[213] M. Timmers,et al. Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers , 2014, Journal of clinical pharmacology.
[214] Jeffrey J. Fong,et al. Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. , 2014, The Annals of pharmacotherapy.
[215] T. van de Casteele,et al. Bioequivalence of a Darunavir/Cobicistat Fixed-Dose Combination Tablet versus Single Agents and Food Effect in Healthy Volunteers , 2014, Antiviral therapy.
[216] C. Stedman,et al. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential , 2014, Therapeutic advances in gastroenterology.
[217] Bin Wang,et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. , 2014, Journal of medicinal chemistry.
[218] Christian Drosten,et al. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS , 2013, Antiviral Research.
[219] O. Chupakhin,et al. [Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]. , 2014, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].
[220] E. Deeks. Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection , 2014, Drugs.
[221] Choongho Lee. Daclatasvir: potential role in hepatitis C , 2013, Drug design, development and therapy.
[222] G. Rossi,et al. Melatonin: its possible role in the management of viral infections-a brief review , 2013, Italian Journal of Pediatrics.
[223] K. Antoniou,et al. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future , 2013, European Respiratory Review.
[224] Yue Wu,et al. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α‐reductase inhibitors , 2013, The Prostate.
[225] Yi Shi,et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.
[226] S. Iwata,et al. Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes , 2013, PloS one.
[227] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[228] Libin Rong,et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.
[229] R. Bellomo,et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. , 2013, American journal of respiratory and critical care medicine.
[230] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[231] W. Oh,et al. Curcuminoids from Curcuma longa and their inhibitory activities on influenza A neuraminidases , 2012 .
[232] Tudor I. Oprea,et al. Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.
[233] S. Ha,et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes , 2012, Diabetologia.
[234] C. Muller,et al. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. , 2012, Antiviral research.
[235] Yong‐Joo Jeong,et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13 , 2012, Bioorganic & Medicinal Chemistry Letters.
[236] D. Davis,et al. Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing , 2012, Antimicrobial Agents and Chemotherapy.
[237] D. Harrich,et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus , 2012, The Biochemical journal.
[238] H. Kato,et al. Melatonin in bacterial and viral infections with focus on sepsis: a review. , 2012, Recent patents on endocrine, metabolic & immune drug discovery.
[239] Tudor I. Oprea,et al. Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.
[240] I. Gonda,et al. Formulation technology to repurpose drugs for inhalation delivery , 2011 .
[241] D. Talmor,et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. , 2011, Chest.
[242] M. Kukhanova,et al. Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo-1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.
[243] P. Nelson,et al. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. , 2010, Cancer research.
[244] R. Purohit,et al. Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease , 2009, Interdisciplinary Sciences: Computational Life Sciences.
[245] P. Sritara,et al. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. , 2009, Asian Pacific journal of allergy and immunology.
[246] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[247] V. A. Maksimov,et al. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. , 2007, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].
[248] A. Chang,et al. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. , 2007, The Cochrane database of systematic reviews.
[249] Dirk Jochmans,et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[250] D. Diz,et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.
[251] F. Calvo,et al. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. , 2005, The American journal of pathology.
[252] G. Glenner,et al. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide , 2004, Histochemie.
[253] M. Lai,et al. Identification of a Ribavirin‐resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy , 2003, Hepatology.
[254] L. Chiang,et al. In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids. , 2003, The Journal of antimicrobial chemotherapy.
[255] J. Peiris,et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.
[256] Rolf Hilgenfeld,et al. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.
[257] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[258] C. Durinx,et al. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV , 2003, Critical reviews in clinical laboratory sciences.
[259] M. Belvisi,et al. Differential Effects of Ebselen on Neutrophil Recruitment, Chemokine, and Inflammatory Mediator Expression in a Rat Model of Lipopolysaccharide-Induced Pulmonary Inflammation , 2002, The Journal of Immunology.
[260] J. Eikelboom,et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.
[261] K. Motomura,et al. The selenoorganic compound ebselen suppresses liver injury induced by Propionibacterium acnes and lipopolysaccharide in rats. , 2001, International journal of molecular medicine.
[262] K. Zilles,et al. Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. , 2000, Archives of biochemistry and biophysics.
[263] I. Goldstein,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.
[264] J. Blay,et al. Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris. , 1999, Antiviral research.
[265] Tom F. Lue,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.
[266] Chika Morimoto,et al. The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.
[267] J. Grzybek,et al. Antiviral activity of the infusion (SHS‐174) from flowers of Sambucus nigra L., aerial parts of Hypericum perforatum L., and roots of Saponaria officinalis L. against influenza and herpes simplex viruses , 1990 .